If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
How do I manage extravasation with Cyramza® (ramucirumab)?
If extravasation occurs or is suspected, follow your local procedures for managing non-vesicant extravasation or use local cold compresses.
Recommendations from the European Society for Medical Oncology - The European Oncology Nursing Society (ESMO-EONS)
The European Society for Medical Oncology-The European Oncology Nursing Society (ESMO-EONS) Clinical Practice Guidelines recommend using local dry cold compresses for non-vesicants such as ramucirumab if extravasation does occur.1
Cyramza is not a vesicant
Ramucirumab is a non-vesicant as it is an antibody in a neutral formulation. It is not likely to cause extravasation.
No dedicated extravasation studies have been conducted in animals. However, local tolerance was investigated in 2 repeat-dose toxicity evaluations in cynomolgus monkeys by clinical observations and as part of the histopathological evaluations.
Intravenous administration of ramucirumab was well tolerated at all dose levels.
Mild, local injection-site reactions were observed and consisted of mononuclear and/or polymorphonuclear cells in the perivascular areas.2